There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiff Oncology (CRDF – Research Report), Evotec AG (EVO – Research Report) and Harpoon Therapeutics (HARP – Research Report) with bullish sentiments.
Cardiff Oncology (CRDF)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cardiff Oncology, with a price target of $15.00. The company’s shares closed last Tuesday at $1.52, close to its 52-week low of $1.13.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Cardiff Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
See today’s best-performing stocks on TipRanks >>
Evotec AG (EVO)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Evotec AG, with a price target of $12.00. The company’s shares closed last Tuesday at $10.14.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Evotec AG has an analyst consensus of Hold, with a price target consensus of $11.50.
Harpoon Therapeutics (HARP)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Harpoon Therapeutics, with a price target of $4.50. The company’s shares closed last Tuesday at $0.67, close to its 52-week low of $0.59.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Harpoon Therapeutics with a $4.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRDF:
- Cardiff Oncology says no deposits held at Silicon Valley Bank
- Cardiff Oncology price target raised to $15 from $14 at H.C. Wainwright
- Cardiff Oncology reports 2022 EPS (89c), consensus (93c)
- Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
- Cardiff Oncology names Fairooz Kabbinavar as Chief Medical Officer
